In the study by Xu et al. [22], the role of the IL-6/STAT3 pathway in the progression and recurrence of HCC and the possibility of its inhibition was described as a possible future therapeutic approach, specifically through monoclonal antibodies specific for IL-6 (Siltuximab and ADL518) and IL-6R (Tocilizumab) or STAT3-activated Jak inhibitors (Ruxolitinib) or STAT3 inhibitors (LLL12 andC188-9). The gene discussed is STAT3; the disease is hepatocellular carcinoma.